Syncona Partners LLP

Syncona Partners LLP is a distinctive London-based healthcare company that operates with a unique model focused on founding, funding, and building global leaders in life science. Unlike traditional venture capital firms that primarily invest in existing companies, Syncona leverages an evergreen capital base to create new ventures from the ground up, often based on pioneering academic research. This long-term approach allows them to provide substantial, sustained capital and deep operational expertise, nurturing companies through their critical early stages and beyond. Their strategic focus is on areas of high unmet medical need, particularly within cell and gene therapies, immunology, oncology, and ophthalmology, where breakthrough science has the potential for transformative patient impact.

The firm's investment strategy is characterized by its high conviction and significant capital commitments. Syncona acts as a primary architect and funder for its portfolio companies, providing the foundational capital necessary to translate cutting-edge science into viable therapeutic solutions. For instance, they committed approximately $38 million (CHF 35 million) as the initial capital for Anaveon in 2020, and a substantial $110 million for Neogene Therapeutics in its Series A in 2020, demonstrating their capacity for large, early-stage investments. This hands-on, company-building approach means their "first cheque" is often a multi-million-dollar commitment designed to fully capitalize a new entity for its initial years of development.

Syncona's financial strength is underpinned by its substantial capital base, with a Net Asset Value (NAV) reported at approximately $1.5 billion USD (£1,234.3 million) as of March 31, 2023. This allows them to make the significant, long-term investments required to bring complex life science innovations to fruition. Their portfolio is typically concentrated, reflecting their deep involvement and belief in the potential of each venture. By combining substantial financial backing with strategic guidance and operational support, Syncona aims to de-risk the development process and accelerate the creation of companies poised to deliver ground-breaking medical advancements globally.